ATE305039T1 - Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist. - Google Patents

Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist.

Info

Publication number
ATE305039T1
ATE305039T1 AT96926062T AT96926062T ATE305039T1 AT E305039 T1 ATE305039 T1 AT E305039T1 AT 96926062 T AT96926062 T AT 96926062T AT 96926062 T AT96926062 T AT 96926062T AT E305039 T1 ATE305039 T1 AT E305039T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
chromosome
gene localized
genes product
Prior art date
Application number
AT96926062T
Other languages
English (en)
Inventor
Ephrat Levy-Lahad
Rudolph E Tanzi
Gerard D Schellenberg
Wilma Wasco
Thomas D Bird
John Mulligan
David J Galas
Original Assignee
Darwin Molecular Corp
Va Medical Ct
Gen Hospital Corp
Ephrat Levy Lahad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Molecular Corp, Va Medical Ct, Gen Hospital Corp, Ephrat Levy Lahad filed Critical Darwin Molecular Corp
Application granted granted Critical
Publication of ATE305039T1 publication Critical patent/ATE305039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96926062T 1995-07-07 1996-07-05 Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist. ATE305039T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95695P 1995-07-07 1995-07-07
US167595P 1995-07-28 1995-07-28
US217495P 1995-08-11 1995-08-11
US232895P 1995-08-14 1995-08-14
PCT/US1996/011386 WO1997003192A2 (en) 1995-07-07 1996-07-05 Chromosome 1 gene and gene products related to alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE305039T1 true ATE305039T1 (de) 2005-10-15

Family

ID=27485043

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926062T ATE305039T1 (de) 1995-07-07 1996-07-05 Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist.

Country Status (7)

Country Link
US (2) US6468791B1 (de)
EP (2) EP0846171B1 (de)
JP (3) JP4073955B2 (de)
AT (1) ATE305039T1 (de)
CA (1) CA2226255A1 (de)
DE (1) DE69635207T2 (de)
WO (1) WO1997003192A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210919B1 (en) 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
JP5379119B2 (ja) * 1995-04-28 2013-12-25 エイチエスシー リサーチ アンド ディベロップメント リミテッド アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
US6531586B1 (en) 1995-04-28 2003-03-11 The Hospital For Sick Children Genetic sequences related to Alzheimer's Disease
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5985564A (en) * 1995-08-16 1999-11-16 President And Fellows Of Harvard College Assay for identifying agents that inhibit chromosome non-disjunction
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
ES2128265B1 (es) * 1997-06-04 2000-03-01 Euroespes S A Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
WO1999035501A1 (en) 1998-01-09 1999-07-15 The Governing Council Of The University Of Toronto Presenilin protein interactions
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2003018991A (ja) * 2001-06-27 2003-01-21 Japan Science & Technology Corp プレセニリン−２遺伝子エキソン５欠損型スプライシング異常の生成に関与する核酸
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007260532B2 (en) * 2006-06-12 2013-06-06 Car-Ber Investments Inc Nozzle testing apparatus and method
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2012358647B2 (en) * 2011-12-20 2015-01-15 Unilever Plc Isotropic liquid detergents comprising soil release polymer
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6210919B1 (en) * 1995-04-28 2001-04-03 Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease

Also Published As

Publication number Publication date
EP0846171A2 (de) 1998-06-10
JP2008035863A (ja) 2008-02-21
CA2226255A1 (en) 1997-01-30
DE69635207D1 (de) 2006-02-02
WO1997003192A3 (en) 1997-04-03
EP1637600A1 (de) 2006-03-22
EP0846171B1 (de) 2005-09-21
US6468791B1 (en) 2002-10-22
JP2001517922A (ja) 2001-10-09
DE69635207T2 (de) 2006-06-22
JP2008035862A (ja) 2008-02-21
US20030180880A1 (en) 2003-09-25
WO1997003192A2 (en) 1997-01-30
JP4073955B2 (ja) 2008-04-09

Similar Documents

Publication Publication Date Title
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
DE69636866D1 (en) Reverse "two-hybrid"-systeme
CY1107552T1 (el) Ly6h γονιδιο
DE69841994D1 (de) 32 Humane sekretierte Proteine
ES2178640T3 (es) Proteina de transferencia de trigliceridos micro9somicos.
ATE405645T1 (de) Genetische sequenzen und proteine bezogen auf alzheimer krankheit und anwendungen davon
EP0947583A3 (de) Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA)
WO2001012776A3 (en) 18 human secreted proteins
WO2000077026A8 (en) 49 human secreted proteins
DE69736002D1 (de) GEN ASSOZIIERT MIT IgA GLOMERULONEPHRITIS
WO2000063230A3 (en) 49 human secreted proteins
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
DE69839765D1 (de) Lage-1 tumor-assozierte nukleinsäuren
PT648836E (pt) Transactivador do mhc de classe ii (ciita) e suas utilizacoes
WO2000058339A3 (en) 50 human secreted proteins
WO2001012775A3 (en) 25 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
ATE236977T1 (de) Verwendung einer rekombinanten dna für die herstellung eines medikaments, wobei die rekombinante dna eine dna umfasst, die die sm1- isoform des proteins der schweren kette von myosin der glatten muskulatur codiert
WO2000061596A8 (en) 50 human secreted proteins
ATE198218T1 (de) Htfiiia gen
EP1428833A3 (de) 207 menschliche sekretierte Proteine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties